SCHEMBL385229

SCHEMBL385229

NC1=CC=CCN(CC(=O)O)C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
ITGB3 P05106 10/20 0.34
ITGA2B P08514 10/20 0.34
KMT2A Q03164 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C19 P33261 2/20 0.34
POLB P06746 1/20 0.34
CYP2C9 P11712 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 1/20 0.32
CYP1A2 P05177 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
AKR1B1 P15121 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11513016 0.75 POLB (0.32) ITGB3ITGA2BKMT2ACYP2D6CYP2C19
SCHEMBL11007717 0.74 ACE (0.31) KMT2ACYP2D6CYP2C19POLBCYP2C9
SCHEMBL11831221 0.71 ACE (0.36) KMT2ACYP2D6CYP2C19POLBCYP2C9
SCHEMBL7144598 0.67 HPGD (0.39) KMT2ACYP2D6CYP2C19POLBCYP2C9
SCHEMBL11626909 0.65
SCHEMBL7349163 0.65 CA12 (0.32) CA12CA9
SCHEMBL917243 0.64 LMNA (0.36) KMT2ACYP2D6CYP2C19POLBCYP2C9
SCHEMBL2865650 0.63 CYP2D6 (0.50) CA12CA9KMT2ACYP2D6CYP2C19
SCHEMBL14876263 0.60 KDM4E (0.67) ITGB3ITGA2BKMT2AKDM4EMEN1
SCHEMBL2713084 0.60 CYP2D6 (0.41) KMT2ACYP2D6CYP2C19POLBCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US claimed
US-9012603-B2 Peptides that block the binding of IgG to FcRn BIOGEN IDEC HEMOPHILIA INC. (US) 2015-04-21 US disclosed
US-8906844-B2 Immunomodulatory peptides BIOGEN IDEC HEMOPHILIA INC. (US) 2014-12-09 US disclosed
US-8101186-B2 Peptides that block the binding of IgG to FcRn SYNTONIX PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20110230639-A1 IMMUNOMODULATORY PEPTIDES SYNTONIX PHARMACEUTICALS INC. (US) 2011-09-22 US disclosed
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn SYNTONIX PHARMACEUTICALS, INC. 2011-03-10 US disclosed
EP-2203471-A2 IMMUNOMODULATORY PEPTIDES SYNTONIX PHARMACEUTICALS, INC. (US) 2010-07-07 EP disclosed
WO-2009020867-A2 IMMUNOMODULATORY PEPTIDES SYNTONIX PHARMACEUTICALS, INC. (US) 2009-02-12 WO disclosed
EP-1639080-A4 A LIBRARY OF PHYLOGENETICALLY RELATED SEQUENCES COGNETIX INC (US) 2008-10-01 EP disclosed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US disclosed
EP-1639080-A2 A LIBRARY OF PHYLOGENETICALLY RELATED SEQUENCES Cognetix, Inc. (US) 2006-03-29 EP disclosed
WO-2004108901-A2 A LIBRARY OF PHYLOGENETICALLY RELATED SEQUENCES COGNETIX, INC. (US) 2004-12-16 WO disclosed
US-20040248189-A1 Method of making a library of phylogenetically related sequences NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-12-09 US disclosed
US-5932733-A INHIBITOR OF THROMBIN CORVAS INTERNATIONAL, INC. (US) 1999-08-03 US disclosed
EP-0765339-B1 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS CORVAS INT INC (US) 1999-01-27 EP disclosed
EP-0765339-A1 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1997-04-02 EP disclosed
WO-1995035313-A1 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1995-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn FCGRT, FCGR3B, FCGR1A CA12 2506/4885CA9 3313/4885ITGB3 588/4885
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A CA12 2506/4885CA9 3313/4885ITGB3 588/4885
US-20110230639-A1 IMMUNOMODULATORY PEPTIDES FCGRT, FCGR3B, FCGR2A CA12 1360/4885CA9 2410/4885ITGB3 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.